Phase 1 clinical trial results indicate Harm Reduction Therapeutics LLC's proposed RiVive OTC naloxone nasal spray has biological results comparable to Rx intramuscular naloxone available in the US.
The trial of the 3-mg nasal spray, identified in HRT's study as HRT001, which delivers an atomized form of 0.1-mL naloxone demonstrated that the bioavailability of the formulation after administration to the subjects was bioequivalent to 0
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?